Endo, other drugmakers sued over ‘pay-for-delay’ deals
The Federal Trade Commission sued Endo Pharmaceuticals and several other drugmakers alleging that they used ‘pay-for-delay’ settlements to block consumers’ access to lower-cost generic versions of Opana ER and Lidoderm....To view the full article, register now.
Already a subscriber? Click here to view full article